Buccolam Європейський Союз - словацька - EMA (European Medicines Agency)

buccolam

neuraxpharm pharmaceuticals s.l. - midazolam - epilepsie - psycholeptika - liečba dlhodobých, akútnych, konvulzívnych záchvatov u dojčiat, batoľatých, detí a adolescentov (od troch mesiacov do menej ako 18 rokov). buccolam musia ich používať len rodičia / opatrovatelia, kde pacient bol diagnostikovaný majú epilepsiu. pre deti od troch do šiestich mesiacov veku, liečba by mala byť v nemocnici nastavenie, kde monitorovanie je možné a resuscitačného vybavenia je k dispozícii.

MYCOMAX 100 Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mycomax 100

zentiva, k.s., Česká republika - flukonazol - 26 - antimycotica (lokÁlne a celkovÉ)

MYCOMAX 150 Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mycomax 150

zentiva, k.s., Česká republika - flukonazol - 26 - antimycotica (lokÁlne a celkovÉ)

MYCOMAX inf Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mycomax inf

zentiva, k.s., Česká republika - flukonazol - 26 - antimycotica (lokÁlne a celkovÉ)

GLUCOMED Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glucomed

laboratoires expanscience, francúzsko - glukózamín - 29 - antirheumatica, antiphlogistica, antiuratica

Zolsketil pegylated liposomal Європейський Союз - словацька - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.